HYPMY
Price
$4.21
Change
+$0.07 (+1.69%)
Updated
Sep 5 closing price
Capitalization
2.7B
IPSEY
Price
$34.85
Change
+$1.14 (+3.38%)
Updated
Sep 5 closing price
Capitalization
11.56B
46 days until earnings call
Interact to see
Advertisement

HYPMY vs IPSEY

Header iconHYPMY vs IPSEY Comparison
Open Charts HYPMY vs IPSEYBanner chart's image
Hypera SA
Price$4.21
Change+$0.07 (+1.69%)
Volume$1.55K
Capitalization2.7B
Ipsen S.A
Price$34.85
Change+$1.14 (+3.38%)
Volume$1.47K
Capitalization11.56B
HYPMY vs IPSEY Comparison Chart in %
Loading...
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IPSEY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HYPMY vs. IPSEY commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HYPMY is a Hold and IPSEY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (HYPMY: $4.22 vs. IPSEY: $34.85)
Brand notoriety: HYPMY and IPSEY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HYPMY: 1% vs. IPSEY: 167%
Market capitalization -- HYPMY: $2.7B vs. IPSEY: $11.56B
HYPMY [@Pharmaceuticals: Generic] is valued at $2.7B. IPSEY’s [@Pharmaceuticals: Generic] market capitalization is $11.56B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HYPMY’s FA Score shows that 2 FA rating(s) are green whileIPSEY’s FA Score has 2 green FA rating(s).

  • HYPMY’s FA Score: 2 green, 3 red.
  • IPSEY’s FA Score: 2 green, 3 red.
According to our system of comparison, IPSEY is a better buy in the long-term than HYPMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HYPMY’s TA Score shows that 4 TA indicator(s) are bullish while IPSEY’s TA Score has 5 bullish TA indicator(s).

  • HYPMY’s TA Score: 4 bullish, 3 bearish.
  • IPSEY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both HYPMY and IPSEY are a good buy in the short-term.

Price Growth

HYPMY (@Pharmaceuticals: Generic) experienced а -0.59% price change this week, while IPSEY (@Pharmaceuticals: Generic) price change was +2.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

IPSEY is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IPSEY($11.6B) has a higher market cap than HYPMY($2.7B). IPSEY has higher P/E ratio than HYPMY: IPSEY (22.26) vs HYPMY (19.64). HYPMY YTD gains are higher at: 43.484 vs. IPSEY (21.901). HYPMY has higher annual earnings (EBITDA): 1.41B vs. IPSEY (1.3B). IPSEY has more cash in the bank: 1.45B vs. HYPMY (1.2B). IPSEY has less debt than HYPMY: IPSEY (869M) vs HYPMY (8.86B). HYPMY has higher revenues than IPSEY: HYPMY (6.66B) vs IPSEY (3.76B).
HYPMYIPSEYHYPMY / IPSEY
Capitalization2.7B11.6B23%
EBITDA1.41B1.3B108%
Gain YTD43.48421.901199%
P/E Ratio19.6422.2688%
Revenue6.66B3.76B177%
Total Cash1.2B1.45B83%
Total Debt8.86B869M1,020%
FUNDAMENTALS RATINGS
HYPMY vs IPSEY: Fundamental Ratings
HYPMY
IPSEY
OUTLOOK RATING
1..100
327
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
31
Undervalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
8191
PRICE GROWTH RATING
1..100
6149
P/E GROWTH RATING
1..100
1113
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HYPMY's Valuation (9) in the null industry is in the same range as IPSEY (31). This means that HYPMY’s stock grew similarly to IPSEY’s over the last 12 months.

IPSEY's Profit vs Risk Rating (40) in the null industry is somewhat better than the same rating for HYPMY (100). This means that IPSEY’s stock grew somewhat faster than HYPMY’s over the last 12 months.

HYPMY's SMR Rating (81) in the null industry is in the same range as IPSEY (91). This means that HYPMY’s stock grew similarly to IPSEY’s over the last 12 months.

IPSEY's Price Growth Rating (49) in the null industry is in the same range as HYPMY (61). This means that IPSEY’s stock grew similarly to HYPMY’s over the last 12 months.

HYPMY's P/E Growth Rating (11) in the null industry is in the same range as IPSEY (13). This means that HYPMY’s stock grew similarly to IPSEY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HYPMYIPSEY
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
51%
Momentum
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
56%
Advances
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 10 days ago
53%
Declines
ODDS (%)
Bearish Trend 26 days ago
70%
Bearish Trend 5 days ago
43%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
65%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IPSEY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ATGYX47.95N/A
N/A
Cantor Fitzgerald Equity Opp Inst
FNRCX42.67N/A
N/A
Fidelity Advisor Energy C
EITMX121.69N/A
N/A
Eaton Vance Tx-Mgd Growth 1.1 I
TROIX15.25N/A
N/A
T. Rowe Price Overseas Stock I
OSTGX16.88N/A
N/A
Osterweis Opportunity Fund

HYPMY and

Correlation & Price change

A.I.dvisor tells us that HYPMY and PLNH have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HYPMY and PLNH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYPMY
1D Price
Change %
HYPMY100%
+1.57%
PLNH - HYPMY
21%
Poorly correlated
+10.91%
CPIX - HYPMY
20%
Poorly correlated
-9.56%
GLASF - HYPMY
20%
Poorly correlated
+3.99%
KMDA - HYPMY
20%
Poorly correlated
+1.13%
JUSHF - HYPMY
18%
Poorly correlated
+6.59%
More

IPSEY and

Correlation & Price change

A.I.dvisor tells us that IPSEY and LBTSF have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPSEY and LBTSF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPSEY
1D Price
Change %
IPSEY100%
+3.39%
LBTSF - IPSEY
15%
Poorly correlated
N/A
LVRLF - IPSEY
9%
Poorly correlated
+1.96%
HYPMY - IPSEY
7%
Poorly correlated
+1.57%
IPSEF - IPSEY
6%
Poorly correlated
N/A
INDV - IPSEY
5%
Poorly correlated
+1.01%
More